• Price to sales forward of Immuneering Corporation – NASDAQ:IMRX TradingView Fri, 10 Jul 2026 10:23:42 GMT
• Enterprise value to EBIT forward of Immuneering Corporation – BOATS:IMRX TradingView Fri, 10 Jul 2026 03:57:56 GMT
• Immuneering Corporation (IMRX) 7500 contracts of August 75 calls as share price up 6.2% StreetInsider Wed, 08 Jul 2026 18:37:20 GMT
• Cantor Fitzgerald initiates Immuneering stock with overweight rating Investing.com Wed, 08 Jul 2026 11:03:27 GMT
• Cantor Fitzgerald Starts Immuneering Corporation (IMRX) at Overweight StreetInsider Wed, 08 Jul 2026 10:07:14 GMT
• Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth simplywall.st Tue, 30 Jun 2026 11:01:14 GMT
• Immuneering Corporation(NasdaqGM: IMRX) added to Russell 2000 Value Benchmark marketscreener.com Mon, 29 Jun 2026 15:47:50 GMT
• Immuneering Corporation(NasdaqGM: IMRX) added to Russell 3000 Value Benchmark marketscreener.com Sun, 28 Jun 2026 22:00:00 GMT
• Immuneering Corporation(NasdaqGM:IMRX) added to Russell Small Cap Completeness Index marketscreener.com Sun, 28 Jun 2026 07:00:00 GMT
• Needham Maintains Immuneering(IMRX.US) With Buy Rating, Maintains Target Price $11 富途牛牛 Sat, 27 Jun 2026 23:47:41 GMT
• Immuneering Corporation (IMRX) Surges 5% as Stock Approaches Key Resistance Level - Up Down Ratio dars.gov.et Sat, 27 Jun 2026 21:48:37 GMT
• IMRX Q1 2026 Earnings: Narrower Loss Drives Optimism for Clinical Pipeline - Earnings Revision Report dars.gov.et Sat, 27 Jun 2026 07:00:00 GMT
• immuneering corp. class a actuals & estimates (nasdaq:imrx) TradingView Fri, 26 Jun 2026 06:35:43 GMT
• form 4 immuneering corp for: 24 june by investing.com Investing.com South Africa Thu, 25 Jun 2026 01:49:50 GMT
• Immuneering CEO Zeskind buys $10,948 in stock By Investing.com Investing.com Canada Thu, 25 Jun 2026 01:43:20 GMT
• immuneering ceo buys 2,400 shares in open market | imrx insider trading Stock Titan Wed, 24 Jun 2026 20:11:49 GMT
• Immuneering (IMRX) CEO buys 2,400 shares in open-market trade Stock Titan Wed, 24 Jun 2026 07:00:00 GMT
• immuneering corp (imrx) technical analysis: support, resistance, indicators & moving averages TradingKey Wed, 24 Jun 2026 07:00:00 GMT
• immuneering corp (imrx) valuation: pe, pb & fair value analysis TradingKey Wed, 24 Jun 2026 07:00:00 GMT
• immuneering | 4: statement of changes in beneficial ownership of securities-director carpenter robert j Moomoo Mon, 22 Jun 2026 05:02:25 GMT
• immuneering stock - weekly review in a volatile biotech market AD HOC NEWS Sat, 20 Jun 2026 15:44:42 GMT
• imrx stock on track for worst day in nearly 5 months — what’s driving the selloff? MSN Fri, 19 Jun 2026 00:19:01 GMT
• immuneering corp (imrx) revenue breakdown: business segments, regional revenue & profit contribution TradingKey Thu, 18 Jun 2026 10:22:01 GMT
• immuneering corp (imrx) dividends & stock splits: historical payouts and event timeline TradingKey Thu, 18 Jun 2026 10:19:43 GMT
• immuneering corp (imrx) shareholder structure: major shareholders & institutional holdings TradingKey Thu, 18 Jun 2026 09:56:39 GMT
• immuneering corp (imrx) earnings forecast: future eps & revenue growth estimates TradingKey Thu, 18 Jun 2026 06:23:21 GMT
• immuneering corp (imrx) technical analysis: support, resistance, indicators & moving averages TradingKey Thu, 18 Jun 2026 05:52:36 GMT
• immuneering corp (imrx) financial health: profitability & balance sheet analysis TradingKey Thu, 18 Jun 2026 05:51:04 GMT
• immuneering corp (imrx) valuation: pe, pb & fair value analysis TradingKey Thu, 18 Jun 2026 05:50:20 GMT
• immuneering corp (imrx) risk assessment: volatility, financial risk & investment risk TradingKey Thu, 18 Jun 2026 05:29:50 GMT
• insider buying: brett hall acquires additional shares of immunee GuruFocus Wed, 17 Jun 2026 05:28:05 GMT
• insider buying: brett hall acquires additional shares of immuneering corp (imrx) GuruFocus Tue, 16 Jun 2026 22:25:32 GMT
• immuneering appoints veteran biotech leader as new cfo The Globe and Mail Tue, 16 Jun 2026 20:40:00 GMT
• Immuneering (NASDAQ: IMRX) CSO purchases 6,035 shares in open-market trade Stock Titan Tue, 16 Jun 2026 07:00:00 GMT
• immuneering corporation announces appointment of andrew gengos to chief financial officer, effective july 16, 2026 marketscreener.com Mon, 15 Jun 2026 13:08:56 GMT
• Ex-Terns CFO from $6.7B Merck buyout to manage Immuneering finances Stock Titan Mon, 15 Jun 2026 07:00:00 GMT
• New CFO Andrew Gengos joins Immuneering (NASDAQ: IMRX) with equity grant Stock Titan Mon, 15 Jun 2026 07:00:00 GMT
• Immuneering names Andrew Gengos as chief financial officer Investing.com Mon, 15 Jun 2026 07:00:00 GMT
• Immuneering Appoints Former Terns Executive Andrew Gengos as CFO citybiz Mon, 15 Jun 2026 07:00:00 GMT
• Immuneering Corporation Announces Chief Financial Officer Changes marketscreener.com Mon, 15 Jun 2026 07:00:00 GMT
• Immuneering Appoints Andrew Gengos as Chief Financial Officer The Manila Times Mon, 15 Jun 2026 07:00:00 GMT
• imrx begins dosing in phase iii pancreatic cancer study, stock up MSN Sun, 14 Jun 2026 13:24:39 GMT
• IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up Yahoo Finance Fri, 12 Jun 2026 07:00:00 GMT
• IMRX Q1 2026 Earnings: Narrowed Loss Exceeds Expectations, Pipeline Progress Underway - Forward Guidance Trends dars.gov.et Fri, 12 Jun 2026 07:00:00 GMT
• immuneering shareholders approve directors and auditor at meeting The Globe and Mail Fri, 12 Jun 2026 07:00:00 GMT
• immuneering corporation files form 8-k with sec detailing company information as of june 11, 2026 Minichart Fri, 12 Jun 2026 07:00:00 GMT
• immuneering | 4: statement of changes in beneficial ownership of securities-director feinberg peter Moomoo Fri, 12 Jun 2026 07:00:00 GMT
• Pancreatic cancer trial tests atebimetinib combo, results expected mid-2028 Stock Titan Thu, 11 Jun 2026 07:00:00 GMT
• Immuneering doses first patient in phase 3 pancreatic cancer trial Investing.com Thu, 11 Jun 2026 07:00:00 GMT
• Immuneering (IMRX) director Diana Hausman awarded 33,350 stock options at $4.12 Stock Titan Thu, 11 Jun 2026 07:00:00 GMT
• immuneering (imrx) director receives 33,350 stock options at $4.12 strike Stock Titan Thu, 11 Jun 2026 07:00:00 GMT
• immuneering announces first patient dosed in pivotal phase 3 mapkeeper 301 trial of atebimetinib + mgnp in first-line pancreatic c... The Manila Times Thu, 11 Jun 2026 07:00:00 GMT
• immuneering corporation initiates pivotal phase 3 mapkeeper 301 trial to evaluate atebimetinib in combination with mgnp for metast... Quiver Quantitative Thu, 11 Jun 2026 07:00:00 GMT
• immuneering | 4: statement of changes in beneficial ownership of securities-director hausman diana Moomoo Thu, 11 Jun 2026 07:00:00 GMT
• imrx stock on track for worst day in nearly 5 months — what’s driving the selloff? MSN Sun, 07 Jun 2026 15:14:31 GMT
• imrx stock on track for worst day in nearly 5 months — what’s driving the selloff? MSN Fri, 05 Jun 2026 13:09:43 GMT
• asco’s biggest winners showcased a new era of cancer innovation BioSpace Wed, 03 Jun 2026 07:00:00 GMT
• oppenheimer reiterates immuneering stock rating on pipeline progress Investing.com Wed, 03 Jun 2026 07:00:00 GMT
• oppenheimer reiterates immuneering stock rating on pipeline progress Investing.com Tue, 02 Jun 2026 16:42:10 GMT
• mizuho defends immuneering corporation (imrx), 'recommend being opportunistic on imrx' StreetInsider Tue, 02 Jun 2026 10:43:32 GMT
• Immuneering Corporation 8-K SEC Filing: Company Information, NASDAQ Listing, and Compliance Details (June 1, 2026) – Minichart Minichart Tue, 02 Jun 2026 07:00:00 GMT
• mizuho reiterates immuneering stock rating after trial data update Investing.com Tue, 02 Jun 2026 07:00:00 GMT
• immuneering stock maintained at outperform by oppenheimer on survival data Investing.com Australia Tue, 02 Jun 2026 07:00:00 GMT
• we're not very worried about immuneering's (nasdaq:imrx) cash burn rate Moomoo Tue, 02 Jun 2026 07:00:00 GMT
• immuneering receives investment bank analyst rating update by investing.com Investing.com India Tue, 02 Jun 2026 07:00:00 GMT
• form 8k immuneering corp for: 1 june by investing.com Investing.com India Tue, 02 Jun 2026 07:00:00 GMT
• atebimetinib demonstrates 17.3 month median overall survival in study geneonline.com Tue, 02 Jun 2026 01:05:45 GMT
• asco26: amid daraxonrasib spotlight, immuneering makes case for its drug in 1l pancreatic cancer FirstWord Pharma Mon, 01 Jun 2026 20:56:30 GMT
• imrx: atebimetinib plus chemo nearly doubled survival in first-line metastatic pancreatic cancer TradingView Mon, 01 Jun 2026 14:40:40 GMT
• oppenheimer reiterates outperform rating on immuneering corporation (imrx) following data StreetInsider Mon, 01 Jun 2026 14:00:28 GMT
• the nasdaq biotechnology index closed down more than 1.8%, with constituent stock immuneering dropping 22.10%. nuvalent, gossamer ... Bitget Mon, 01 Jun 2026 10:14:42 GMT
• ASCO: Biopharma has pancreatic cancer ‘surrounded’ as Immuneering’s drug adds 9 quality months BioSpace Mon, 01 Jun 2026 07:00:00 GMT
• Pancreatic cancer drug combo shows 17.3-month survival in trial Stock Titan Mon, 01 Jun 2026 07:00:00 GMT
• Immuneering stock maintained at Outperform by Oppenheimer on survival data Investing.com Mon, 01 Jun 2026 07:00:00 GMT
• Immuneering reports median survival data from pancreatic trial Investing.com Mon, 01 Jun 2026 07:00:00 GMT
• IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff? Stocktwits Mon, 01 Jun 2026 07:00:00 GMT
• asco26: with daraxonrasib in the spotlight, immuneering makes case for its drug in 1l pancreatic cancer FirstWord Pharma Mon, 01 Jun 2026 07:00:00 GMT
• [8-k] immuneering corp reports material event | imrx 8-k filing Stock Titan Mon, 01 Jun 2026 07:00:00 GMT
• immuneering corporation reports promising 17.3 months median overall survival in first-line pancreatic cancer trial with atebimeti... Quiver Quantitative Mon, 01 Jun 2026 07:00:00 GMT
• immuneering presents compelling 17.3-month median overall survival and favorable tolerability with atebimetinib plus chemotherapy ... marketscreener.com Mon, 01 Jun 2026 07:00:00 GMT
• atebimetinib demonstrates 17.3 month median overall survival in study geneonline.com Mon, 01 Jun 2026 07:00:00 GMT
• immuneering reports 17.3-month survival data for pancreatic cancer drug by investing.com Investing.com India Mon, 01 Jun 2026 07:00:00 GMT
• according to a document submitted to the u.s. securities and exchange commission, as of april 24, 2026, biotechnology company immu... Bitget Mon, 01 Jun 2026 06:03:05 GMT
• immuneering corp stock (us45255l1089): imrx trades around 5.36 usd ahead of key june data AD HOC NEWS Thu, 28 May 2026 07:00:00 GMT
• IMRX Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline - Guidance Revision Trend dars.gov.et Wed, 27 May 2026 07:00:00 GMT
• ASCO to spotlight pancreatic cancer innovation beyond KRAS BioCentury Sat, 23 May 2026 07:00:00 GMT
• IMRX Jumps As Immuneering Extends Cash Runway And Trial Pipeline StocksToTrade Fri, 22 May 2026 07:00:00 GMT
• IMRX Jumps As Immuneering Touts Atebimetinib Pipeline Momentum timothysykes.com Fri, 22 May 2026 07:00:00 GMT
• mek inhibitor delivers 17.3-month os for pancreatic cancer BioWorld News Fri, 22 May 2026 07:00:00 GMT
• immuneering reports 17.3 months median overall survival in first-line metastatic pancreatic cancer patients treated with atebimeti... The Manila Times Fri, 22 May 2026 07:00:00 GMT
• mizuho securities maintains immuneering(imrx.us) with buy rating, maintains target price $12 Moomoo Fri, 22 May 2026 07:00:00 GMT
• immuneering reports 17.3-month survival in pancreatic cancer trial by investing.com Investing.com Australia Fri, 22 May 2026 07:00:00 GMT
• immuneering stock jumps on pancreatic cancer trial data by investing.com Investing.com South Africa Fri, 22 May 2026 01:33:32 GMT
• imrx q1 2026 earnings: narrowing losses drive positive surprise as immuneering advances pipeline - earnings yield analysis Newser Fri, 22 May 2026 00:33:16 GMT
• immuneering reports 17.3 months median overall survival in first-line metastatic pancreatic ... Hastings Tribune Thu, 21 May 2026 21:09:48 GMT
• Immuneering Corporation to Present Phase 2a Trial Results for Atebimetinib at ASCO Annual Meeting on June 1, 2026 Quiver Quantitative Thu, 21 May 2026 07:00:00 GMT
• Pancreatic cancer trial of Immuneering drug hits 17.3-month median survival Stock Titan Thu, 21 May 2026 07:00:00 GMT
• Immuneering stock jumps on pancreatic cancer trial data By Investing.com Investing.com Nigeria Thu, 21 May 2026 07:00:00 GMT
• Immuneering reports 17.3-month survival in pancreatic cancer trial By Investing.com Investing.com Canada Thu, 21 May 2026 07:00:00 GMT
• immuneering corp stock (us45255l1089): clinical updates keep biotech investors watching AD HOC NEWS Thu, 21 May 2026 07:00:00 GMT
• needham maintains immuneering(imrx.us) with buy rating, maintains target price $11 Moomoo Thu, 21 May 2026 07:00:00 GMT
• chardan capital maintains immuneering(imrx.us) with buy rating, maintains target price $20 富途牛牛 Wed, 20 May 2026 05:06:54 GMT
• chardan capital maintains immuneering(imrx.us) with buy rating, maintains target price $20 Moomoo Tue, 19 May 2026 21:32:00 GMT
• mizuho securities sticks to their buy rating for immuneering (imrx) The Globe and Mail Tue, 19 May 2026 11:04:00 GMT
• immuneering price target maintained with a $20.00/share by chardan capital Moomoo Tue, 19 May 2026 07:00:00 GMT
• immuneering inks supply agreement with eli lilly for latter’s investigational cancer therapy: retail looks to buy the stock on dip... MSN Mon, 18 May 2026 16:26:34 GMT
• Can Revolution’s 'miracle' pancreatic cancer drug be topped? Immuneering, Actuate say yes BioSpace Mon, 18 May 2026 07:00:00 GMT
• immuneering stock (us45255l1089): insider buying puts the biotech back in focus Ad-hoc-news.de Sun, 17 May 2026 07:00:00 GMT
• immuneering corporation reports q1 2026 financial results and announces positive phase 2a pancreatic cancer trial data – minichart... Minichart Sat, 16 May 2026 07:00:00 GMT
• number of shareholders of immuneering corporation – nasdaq:imrx TradingView Fri, 15 May 2026 20:33:46 GMT
• immuneering corp q1 2026 10-q report: financial results, risk factors, and forward-looking statements Minichart Fri, 15 May 2026 20:04:00 GMT
• immuneering corporation reports q1 2026 financial results and announces positive phase 2a pancreatic cancer trial data Minichart Fri, 15 May 2026 16:20:00 GMT
• immuneering (imrx) reports q1 2026 results with $198.6m cash grafa.com Fri, 15 May 2026 15:46:00 GMT
• immuneering corp 1q 2026: revenue ($13.78m), net income ($13.46m), eps ($0.21) — 10-q summary TradingView Fri, 15 May 2026 12:01:01 GMT
• immuneering posts smaller-than-expected q1 net loss on lower r&d spend TradingView Fri, 15 May 2026 11:43:44 GMT
• immuneering reports q1 2026 financial results and clinical updates StreetInsider Fri, 15 May 2026 11:36:12 GMT
• Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates The Manila Times Fri, 15 May 2026 07:00:00 GMT
• pancreatic cancer patient gets 27 months progression-free on immuneering drug Stock Titan Fri, 15 May 2026 07:00:00 GMT
• immuneering to present pancreatic cancer trial data at asco Investing.com Fri, 15 May 2026 07:00:00 GMT
• needham maintains immuneering(imrx.us) with buy rating, maintains target price $11 Moomoo Fri, 15 May 2026 07:00:00 GMT
• immuneering reports q1 2026 net loss $13.5m, $198.6m cash runway into 2029 TradingView Fri, 15 May 2026 07:00:00 GMT
• pancreatic data and cash runway into 2029 at immuneering (nasdaq: imrx) Stock Titan Fri, 15 May 2026 07:00:00 GMT
• immuneering corporation reports earnings results for the first quarter ended march 31, 2026 marketscreener.com Fri, 15 May 2026 07:00:00 GMT
• imrx: clinical advances and strong cash runway highlight q1 2026, with net loss narrowing year-over-year TradingView Fri, 15 May 2026 07:00:00 GMT
• immuneering (imrx) advances atebimetinib into mapkeeper 301 phase 3 Stock Titan Fri, 15 May 2026 07:00:00 GMT
• immuneering corp stock (us45255l1089): q4 beat and 174% ytd surge AD HOC NEWS Thu, 14 May 2026 15:37:53 GMT
• Immuneering Corporation: Updates Inbound At The End Of The Month (NASDAQ:IMRX) Seeking Alpha Tue, 12 May 2026 07:00:00 GMT
• immuneering backs national cancer research month awareness effort Traders Union Thu, 07 May 2026 23:36:34 GMT
• immuneering’s phase 3 pancreatic cancer trial puts atebimetinib in the spotlight for imrx investors TipRanks Thu, 07 May 2026 07:00:00 GMT
• We're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash Wisely Yahoo Finance Wed, 06 May 2026 07:00:00 GMT
Immuneering Corporation(NASDAQ:IMRX) 
Immuneering Corporation provides genetic, genomic, and proteomic data analysis services for pharmaceutical companies to generate biological insights that enhance the clinical and commercial success of medicines. The company was incorporated in 2008 and is based in Cambridge, Massachusetts.
Website: https://immuneering.com/
Founded: 2008
CEO / Co-Founder: Ben Zeskind
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends